Title: A Phase 1 Dose Escalation Study of PRS-343, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-positive MalignanciesPresentation Number: 525ODate/Time: Sunday, September 20, 2020, 10:32 AM ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback